AbbVie Inc. is a Delaware corporation that researches, develops, manufactures and sells prescription medicines and aesthetic products. Its 10-K groups its products into immunology, neuroscience, oncology, aesthetics and eye care. Its corporate offices and principal executive offices are at 1 North Waukegan Road in North Chicago, Illinois, and its common stock trades on the New York Stock Exchange as ABBV.
Identity
- Legal name (10-K cover): AbbVie Inc.
- Ticker and exchange: ABBV, New York Stock Exchange (also listed on NYSE Texas)
- State of incorporation: Delaware (incorporated April 10, 2012)
- SEC CIK: 0001551152 (SEC commission file number 001-35565)
- Fiscal year end: December 31
- Category: Pharmaceuticals and life sciences; biopharmaceutical company
Origin
AbbVie became an independent, publicly traded company on January 1, 2013, when Abbott Laboratories distributed 100% of AbbVie’s outstanding common stock to Abbott’s shareholders.
Business structure and 2025 net revenues
The Form 10-K for the year ended December 31, 2025 states that AbbVie operates as a single global business segment. Net revenues were $61,160 million in 2025. The 10-K reports that Skyrizi and Rinvoq each represented more than 10% of total net revenues, and that net revenues outside the United States were approximately 24% of the total.
| Area | Product | 2025 net revenues (USD millions) |
|---|---|---|
| Immunology | Skyrizi | 17,562 |
| Immunology | Rinvoq | 8,304 |
| Immunology | Humira | 4,540 |
| Neuroscience | Botox Therapeutic | 3,769 |
| Neuroscience | Vraylar | 3,621 |
| Oncology | Imbruvica (U.S. product revenue plus collaboration revenue outside the U.S.) | 2,869 |
| Oncology | Venclexta | 2,792 |
| Aesthetics | Botox Cosmetic | 2,602 |
| Aesthetics | Juvederm Collection | 993 |
Workforce and facilities
As of December 31, 2025, AbbVie employed approximately 57,000 people in more than 70 countries. The 10-K says it owns or leases approximately 600 facilities worldwide with about 19.4 million square feet of floor space for production, distribution and administration. Its list of significant manufacturing sites includes North Chicago and Abbott Park in Illinois, Barceloneta in Puerto Rico, Worcester in Massachusetts, Cork, Sligo and Westport in Ireland, Ludwigshafen in Germany and Singapore.
How to verify this company yourself
- SEC EDGAR filer page for AbbVie Inc. (CIK 0001551152)
- Form 10-K for fiscal year 2025 (cover page, Item 1 business, Item 2 properties)
- AbbVie Contact Center (customer service, adverse events, corporate, media and investor contacts)
- AbbVie investor relations contact information (transfer agent)
Location and contact
- Corporate offices and principal executive offices (10-K cover): 1 North Waukegan Road, North Chicago, IL 60064-6400
- Main telephone (10-K cover): +1 847-932-7900
- AbbVie Customer Service (company contact center, United States locations page): +1 800-255-5162
Last verified: November 6, 2026. Sources: AbbVie Form 10-K for fiscal 2025 (filed February 20, 2026); SEC EDGAR submissions record for CIK 0001551152; AbbVie contact center locations page; AbbVie investor relations contact page.
Directory listing. Not investment advice, not a product review, and not medical advice. Product names and revenue figures are those published in the company’s 10-K.
Listing type: Editorial. Not claimed by the company. Not sponsored. Send a correction.
